Several brokerages have updated their recommendations and price targets on shares of Onconova Therapeutics (NASDAQ: ONTX) in the last few weeks:

  • 1/18/2018 – Onconova Therapeutics had its “buy” rating reaffirmed by analysts at HC Wainwright. They now have a $6.00 price target on the stock.
  • 1/17/2018 – Onconova Therapeutics was downgraded by analysts at Maxim Group from a “buy” rating to a “hold” rating.
  • 1/10/2018 – Onconova Therapeutics was upgraded by analysts at Zacks Investment Research from a “sell” rating to a “hold” rating. According to Zacks, “Onconova Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company. It focuses on discovering and developing small molecule drug candidates to treat cancer. The Company’s products under different phases of development include Rigosertib intravenous (IV), Rigosertib Oral, Rigosertib IV, ON 013105 and Recilisib. Onconova Therapeutics, Inc. is headquartered in Newtown, Pennsylvania. “
  • 1/4/2018 – Onconova Therapeutics was given a new $6.00 price target on by analysts at HC Wainwright. They now have a “buy” rating on the stock. They wrote, “Rigosertib Expanding Footprint; Moving Forward With CRADA to Address RASopathies Moving forward on RASopathies with NCI. Onconova announced today that it has entered into a Cooperative Research and Development Agreement (CRADA) with the National Cancer Institute (NCI) for the development of rigosertib in pediatric cancer associated RASopathies. The NCI is to conduct and fund the majority of research, including preclinical laboratory studies and a clinical trial, whereas Onconova is expected to provide rigosertib and initial funding for non-clinical studies. The studies are slated to start in 2018. The NCI is to focus on RASopathy related cancers in pediatric patients, whereas Onconova is expecting to focus on Juvenile Myelomonocytic Leukemia (JMML). This event signifies the potential expansion of rigosertib use in a number of cancers and syndromes driven by RAS pathway hyperactivation.””
  • 12/19/2017 – Onconova Therapeutics was given a new $6.00 price target on by analysts at HC Wainwright. They now have a “buy” rating on the stock.
  • 12/12/2017 – Onconova Therapeutics was given a new $6.00 price target on by analysts at HC Wainwright. They now have a “buy” rating on the stock.
  • 12/12/2017 – Onconova Therapeutics was downgraded by analysts at Zacks Investment Research from a “hold” rating to a “sell” rating. According to Zacks, “Onconova Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company. It focuses on discovering and developing small molecule drug candidates to treat cancer. The Company’s products under different phases of development include Rigosertib intravenous (IV), Rigosertib Oral, Rigosertib IV, ON 013105 and Recilisib. Onconova Therapeutics, Inc. is headquartered in Newtown, Pennsylvania. “

Onconova Therapeutics Inc (NASDAQ:ONTX) opened at $1.77 on Monday. The company has a market capitalization of $19.06, a P/E ratio of -0.58 and a beta of 0.10. Onconova Therapeutics Inc has a fifty-two week low of $1.21 and a fifty-two week high of $3.88.

Onconova Therapeutics (NASDAQ:ONTX) last posted its earnings results on Thursday, November 9th. The biopharmaceutical company reported ($0.71) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.73) by $0.02. The company had revenue of $0.11 million during the quarter, compared to analyst estimates of $0.29 million. Onconova Therapeutics had a negative return on equity of 558.97% and a negative net margin of 2,855.94%. sell-side analysts predict that Onconova Therapeutics Inc will post -2.82 EPS for the current fiscal year.

Onconova Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company operates through the identification and development of oncology therapeutics segment. It is focused on discovering and developing small molecule drug candidates to treat cancer. The Company has created a targeted anti-cancer agents designed to work against specific cellular pathways that are important to cancer cells.

Receive News & Ratings for Onconova Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Onconova Therapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.